SCHEMBL2935262

SCHEMBL2935262

Cc1ccc(C(=O)NC[C@H](NC(=O)c2ccc(-c3ccccc3)cn2)C(=O)N[CH]CC(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.46
CTSA P10619 1/20 0.44
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 5/20 0.41
DGAT1 O75907 1/20 0.41
CNR1 P21554 2/20 0.40
CTSB P07858 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MME P08473 1/20 0.38
NFKB1 P19838 1/20 0.38
PSMB5 P28074 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927696 0.87 CTSA (0.44) CTSANPC1RAB9ASMN1; SMN2CTSB
SCHEMBL2931860 0.87 KMT2A (0.53) MEN1KMT2APSMB5
SCHEMBL2931806 0.85 HDAC3 (0.40) EGLN1NPC1RAB9ACNR1MEN1
SCHEMBL2935265 0.85 NPC1 (0.56) EGLN1CTSANPC1RAB9ASMN1; SMN2
SCHEMBL2930960 0.84 DHODH (0.47) NPC1RAB9ASMN1; SMN2HIF1ADGAT1
SCHEMBL2927821 0.84 KMO (0.38) NPC1RAB9ASMN1; SMN2CNR1CTSB
SCHEMBL2929285 0.84 CNR2 (0.40) CTSANPC1RAB9ASMN1; SMN2CNR1
SCHEMBL2930927 0.84 HDAC1 (0.47) CTSANPC1RAB9ASMN1; SMN2CTSB
SCHEMBL2935254 0.84 CNR2 (0.52) CTSACNR1PSMB5
SCHEMBL2930530 0.84 GRN (0.52) NPC1RAB9ACNR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 EGLN1 1326/4885CTSA 209/4885NPC1 2169/4885
US-20090075936-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 EGLN1 1326/4885CTSA 209/4885NPC1 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.